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Can an app supporting psoriasis patients
improve adherence to topical treatment? A
single-blind randomized controlled trial
Mathias Tiedemann Svendsen1,2,3,4* , Flemming Andersen1,5, Kirsten Hammond Andersen5
and Klaus Ejner Andersen1,2,5
Abstract
Background: Topical corticosteroid or corticosteroid/calcipotriol preparations are recommended first-line topical
treatments of psoriasis, but a main cause for the lack of efficacy of topical treatments is considered low rates of
adherence to topical drugs. Patient support by the use of applications (apps) for smartphones is suggested to
improve medical adherence.
Methods/design: Design: An investigator-initiated, single-center, single-blind, parallel-group, phase-4 clinical
superiority randomized controlled trial (RCT). Participants: 134 patients 18 to 75 years of age with mild-to-moderate
psoriasis, who are capable of reading English language, own a smartphone, and are candidates for the study drug
calcipotriol and betamethasone dipropionate (Cal/BD) cutaneous foam once daily prn (pro re nata). Intervention: A
28-day adherence-supporting app providing compulsory daily treatment reminders that pop-up on the smartphone
screen with a short alert sound. The app synchronizes through Bluetooth® to an electronic monitor (EM) attached
to the medication canister. The EM contains a chip registering the amount of foam, day and time the patient use
the foam dispenser. The information is displayed in a diary that shows the amount of Cal/BD cutaneous foam used
and the number of applied treatment sessions. The app has an optional diary with the patient’s rating of
symptoms. Non-intervention: Use of Cal/BD cutaneous foam and EM without the app. All participants are prescribed
Cal/BD cutaneous foam prn for the entire study period.
Primary outcome obtained in week 4: rates of adherence measured by patient report, weight of medication canisters,
and number of treatment sessions measured by the EM. Secondary outcomes obtained at baseline, weeks 4, 8, and
26: Lattice System Physician’s Global Assessment (LS-PGA) and Dermatology Quality of Life Index (DLQI).
Discussion: This trial tests of whether an app can improve rates of adherence to a topical antipsoriatic drug. If the
app improves rates of adherence and reduces the burden of psoriasis in a clinically significant way, the app could
easily be implemented as a standard routine of care in the clinic.
Trial registration: NCT02858713, registered on August 3, 2016. EudraCT number 2016–002143-42.
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Background
Psoriasis affects 2 to 4% of the Western population
[1]. Topical calcipotriol and betamethasone dipropio-
nate (Cal/BD) cutaneous foam is one of the safe and
effective recommended first-line topical treatments of
mild-to-moderate psoriasis [2, 3]. For a satisfactory
treatment result, adherence to the doctor’s treatment
plan prescribed for the topical treatment is considered
central for the treatment result, but Storm et al. [4]
reported that one out of three prescriptions were
never filled at the pharmacy. According to Urquhart
et al. [5], lack of efficacy from the treatment is caused
by non-adherence, non-absorption or non-response.
Of the three causes for lack of efficacy, the clinician
may primarily influence medical adherence. This mo-
tivated our psoriasis research group to test whether
one of the ubiquitous, presumably cost-effective, and eas-
ily accessible adherence-supporting technological solu-
tions could increase adherence rates and, in addition,
whether this solution reduces the severity of psoriasis and
improves quality of life when tested in a high-quality and
sufficiently powered randomized clinical trial (RCT).
The design of the study is based on evidence from the
results of a Cochrane review [6] and a trilogy of reviews
of recently-published literature by our research group
[7–9], which extracted data on medical adherence rates
in studies of psoriasis patients treated with topical cor-
ticosteroid compounds with an emphasis on: 1) determi-
nants of medical non-adherence and 2) interventions
that can improve rates of medical adherence.
Twelve original studies addressing adherence to topical
corticosteroid treatments have been published consisting of
5 questionnaire surveys [10–14], 2 prospective studies [15,
16], 1 qualitative study [17], 1 mixed-method study [18], 1
register study [19], and 2 intervention studies [20, 21]. The
observation periods varied with up to a year’s follow-up time.
The rates of secondary medical non-adherence (whether
prescription-only medicine picked up from the pharmacy
was used) varied from 8 to 88.3% [10–12, 14–16, 18, 19, 22].
The rates of medical non-adherence were stated as follows:
1) patient-reported on eight non-validated scales [10–12,
14–16, 18, 19] and one validated scale [13], 2) objectively by
a ratio of expected consumption compared with actual use
(measured by the weight of the corticosteroid compound
used) in two studies [15, 16], 3) objectively reported as pri-
mary non-adherence (whether written prescriptions are
filled) or persistence (time from when the first prescription is
filled until the end of treatment) measured via records of
filled prescriptions in two studies [16, 19], and 4) number of
treatment sessions measured by an electronic monitor (EM)
[21]. The literature described 34 multifactorial determinants
of medical non-adherence [10–12, 14, 15, 17, 18], where for-
getfullness was the most frequently reported determinant
[11, 15, 18]. The interventions consisted of an individualized
patient-supported educational program conducted at derma-
tology clinics [20] and weekly patient reporting to a webpage
[21]. The interventions improved medical adherence during
the study periods. One of the intervention studies had a
long-term follow-up period of 1 year [21]. Generally speak-
ing, the studies were heterogeneous with a high risk of bias.
The conclusions and recommendations from the literature
reviews [7] and Cochrane review [6] are:
1) There is a lack of randomized, controlled clinical
studies with sufficient power to test the effect of
adherence-seeking interventions; 2) intervention studies
can make use of technical support, e.g. apps for smart-
phones [23–25] or reminder messages sent to mobile
telephones [26]; and 3) the formulation and exact type
of the corticosteroid product should be stated.
This led us to conduct this superiority RCT, described
in the following.
Methods/design
Study objectives
The single-blind investigator-initiated trial (Additional file 1)
is an intervention study with an intention to treat (ITT) ana-
lysis that compares use of Cal/BD cutaneous foam with an
EM-unit (SmarTop™ number 053776) to use of Cal/BD cuta-
neous foam with a patient-supporting app (MyPso Smar-
Top™ Version 1.0) that synchronizess via Bluetooth® to the
EM unit.
Intervention: Detailed description of the app
The EM unit and app are designed and owned by LEO®
Pharma (LEO®). The app design is based on results from
systematic literature reviews on adherence to topical
antipsoriatic treatments [7, 8] with the goal of improving
adherence rates. The app focuses on reducing forgetfull-
ness, and at the same time incorporates functionalities
that motivate (i.e. nudge) patients to use their medica-
tion [27] and thereby reduce obtrusive behaviors towards
medication [28].
The patient-support app, combined with the EM
unit, has three functions: 1) to provide patients with
a measurement of their consumption of medicine by
synchronizing to the EM (that contains a chip regis-
tering the amount of foam, day and time the patient
use the foam dispenser), 2) to measure the severity of
their psoriasis by having the patients state their symp-
toms in a diary (optional) and 3) to support patients
in their treatment and refills through compulsory re-
minder messages that once daily pop up on the
smartphone screen with a short alert sound and
through use of optional educational and motivational
text materials in the app.
The EM developed for the trial can only monitor the
number of treatment sessions when attached to a canister
with Cal/BD cutaneous foam produced and manufactured
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by LEO®. Since Cal/BD cutaneous foam can be ex-
pected to be more expensive than similar corticoster-
oid compounds, Cal/BD cutaneous foam will be
supplied to all trial participants for treatment 1 hora
somni (hs) pro re nata (prn) for the entire study
period. The product has been approved for the Da-
nish market since May 2016 [29].
Recruitment
In order to ensure uniform treatment and accurate data
collection, the Dermatology Department in Odense will
be the only recruitment and trial site. Investigator MTS
will see all participants himself. MTS will include pa-
tients referred from a planned consultation with the
dermatology outpatient clinic or recruited by advertising,
through local newspapers or social media platforms. If
the number of participants included/year is less than 60,
contact with the region’s specialists for the referral of
psoriasis patients is planned.
Null hypothesis
There is no difference in medical adherence to a topical
Cal/BD product among psoriasis patients using the app
(the intervention group) versus those without access to
the app (the non-intervention group).
Thesis: The purpose of the trial is to test the null
hypothesis.
Endpoints and data collection
Primary outcome measurements
Studies should measure rates of secondary medical ad-
herence by the following ratio: the expected quantity of
topical product estimated to be used during the study
period at the start of the study compared with the medi-
cine consumed by the end of the study.
Medicinal use should be measured by an EM, a device
attached to the top of the canister containing the study
drug, which measures the number of treatment sessions
in the treatment period [30]. In this study, we have chosen
to use a study-specific EM designed by LEO®. Measuring
the number of treatment sessions over the treatment
period is considered superior to other methods for meas-
uring medical adherence, such as checking the weight of
the medicine used or patient-reported adherence rates.
Primary endpoint (for adherence) in week 4 is the fol-
lowing relationship: Number of treatment sessions with
Cal/BD cutaneous foam in a 28-day treatment period/
number of expected treatment sessions in a 28-day treat-
ment period.
Data is collected from the EM on the number of treat-
ment sessions in the treatment period. For a comparison
of methods, the adherence rate reported by the partici-
pant and based on the medicine used as measured by
electronic weight is also recorded in week 4.
Secondary outcome measurements
It should be studied whether increased consumption
of prescribed medicine also results in an improvement
of illness-related surrogate endpoints, which should
be related to both the quality of life and severity of
the disease.
For this study, the validated Lattice System Physician’s
Global Assessment (LS-PGA), which combines extent,
redness, scaling, and thickness of psoriasis [31–34] and
the validated Dermatology Life Quality Index (DLQI), a
questionnaire for how skin disease has affected the pa-
tient’s life quality in the past week up to measurement
[35] have been chosen.
The secondary outcome measurements are obtained at
baseline, week 4, week 8, and week 26 (see Table 1). The
LS-GPA is estimated by the investigator by objective
clinical investigation. The DLQI questionnaire is an-
swered by the participants on a sheet of paper at all
consultations.
Specification and justification of effect parameters
Electronic monitoring of secondary medical adherence is
deemed to be the best quality method for measuring
whether the participant has used the medicine as
prescribed [8, 30]. LS-GPA is a validated outcome meas-
urement for the estimation of the disease activity of
mild-to-moderate psoriasis. DLQI is a validated outcome
measurement that, over the last 15 years, has been used
in the clinic and dermatological research literature.
Data that is considered as source data
The following source data will be recorded for the spon-
sor in the Case Report Form (CRF) and stored in the
data program Research Electronic Data Capture (REDCap):
Civil registration number, gender, age, duration of psoriasis,
previous and current systemic treatments for psoria-
sis, local treatments for psoriasis used in the last 6
months prior to the study, socio-economic condi-
tions (relationship status, education, job function),
information as to whether the subject is pregnant or
breastfeeding at the time of the study, LS-PGA and
DLQI estimated in the clinic, and the test drug sup-
plied with statement of batch numbers, the investi-
gator’s assessment of the number of treatment
sessions over 4 weeks of treatment, and the weight
of the Cal/BD cutaneous foam product that is
assessed as necessary for a four-week treatment
period, the number of treatment days over the treat-
ment period until the psoriasis is relieved, the num-
ber of days with psoriasis until it is relieved, the
quantity of Cal/BD cutaneous foam actually used
over a four-week treatment period, and the partici-
pant’s own assessment of the number of treatment
sessions over a four-week treatment period.
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Handling and storing of data
All study-relevant data will be stored in the CRF in a
paper form and in REDCap. The trial master file will be
stored in a printout in a binder that will be stored in a
locked, fireproof cabinet at the investigator’s office.
After participants have returned the EM in week 4,
it will be returned to the firm BridgeIT, which is in
charge of reading the EM, and, subsequently, handed
over to LEO®, which is in charge of discarding the
EMs. Data from reading the EMs at BridgeIT, con-
nected to a test-subject-unique identification number
and stored in an Excel spreadsheet, will be returned
by BridgeIT to the investigator. The data can in no
way by BridgeIT or LEO® be linked to a civil registra-
tion number or name.
After the end of the study and after the reports have
been submitted to the authorities, the sponsor will store
the data at a secure, locked site for 5 years.
Access to source data and documents
At any time, the investigator will provide direct access to
monitoring, auditing and/or inspection by the Committee
on Health Research Ethics, the Danish Medicines Agency,
or health authorities from other countries.
The participant’s medical chart is source data for in-
clusion and exclusion criteria and the progress of the
treatment. The evaluation of the effect parameters (data
from the EM, app, and questionnaire) will be stored in
the CRF. The GCP unit will pay a monitoring visit to
the trial site six times during the trial.
Inclusion criteria
The following psoriasis patients will be recruited for this
study:
 Legally competent patients of sound mind between
18 and 75 years of age
 Mild-moderate plaque and guttate type psoriasis
 The psoriasis must be visible to the investigator at
the baseline visit)
 Users of smartphones (the app can be used in most
types of smartphone)
 Access to a private e-mail.
During the trial, fertile women must use a reliable
form of contraception, e.g. intrauterine device (IUD) or
hormonal contraception (including birth-control pill,
implant, transdermal contraceptive patch, vaginal ring or
Table 1 Enrollment, intervention, and assessment schedule
Study period
Time points Enrollment Allocation Post allocation Close-out
Baseline Baseline Baseline Week 4 Week 8 Week 26 Week 26
Enrollment:
Eligibility screen X
Informed consent X
Allocation X
Intervention arm:
App
Cal/BD
Non-intervention arm:
Cal/BD
Assessments:
Socio-demographics X
Adverse events X X X X
Primary outcomes
Rates of adherence: X
Patient report
Weight of foam canisters
No. treatment sessions
Secondary outcomes
LS-PGA X X X X
DLQI X X X X
Enrollment, allocation and assessments. List of abbreviations: Cal/BD: Calcipotriol/Betamethasone Dipropionate cutaneous foam; DLQI: Dermatology Quality of Life
Index; BSA: Body Surface Area;LS-PGA: Lattice System Physician’s Global Assessment
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birth control injection), have a sterile partner, or use dual
barriers during the trial period and for at least 14 days
after the study ends. Prior to inclusion in the trial, evi-
dence of a negative pregnancy test must be provided.
Breastfeeding, pregnancy, and the lack of use of reliable
contraception in fertile women are exclusion criteria.
No risk for pregnant or breastfeeding women from a
daily use of Cal/BD cutaneous foam at a maximal dose
for 4 weeks has been reported. Nevertheless, the investi-
gator has chosen the above-mentioned conservative
method in order not to subject fertile women and any
unborn fetuses to unnecessary risk.
Exclusion criteria
The following psoriasis patients will be excluded from
this study:
 Minors and patients over 75 years of age
 Legally incompetent patients or patients not of
sound mind
 Patients for whom a psoriasis diagnosis cannot be
objectified at the consultation
 Patients with severe psoriasis, including
erythrodermic and pustular psoriasis
 Lack of possession of or ability to use a smartphone
 Breastfeeding or pregnant patients or fertile women
who do not use reliable contraception
 Patients who are allergic to one of the ingredients in
the Cal/BD cutaneous foam preparation.
With the installation of the app for the smartphone,
the laboratory technician will ensure that: 1) the EM
synchronizes to the app through Bluetooth® and 2) the
app with a reminder function are set up correctly and
function on the participant’s smartphone. If this is not
the case, the participant will be excluded.
Criteria for exclusion during the study
There are four criteria that must be fulfilled to be re-
moved from the study: 1) withdrawal of consent at the
last study visit in week 26, which entails that the data
will not be included in the analysis from the study, 2) a
serious adverse event (SAE) occurs in which a partici-
pant discontinues, 3) for fertile women, the occurrence
of pregnancy, and 4) failure to keep appointments or to
return the EM with legible data.
If there is a suspicion of a serious adverse event (SAE),
the study’s investigator must immediately be contacted,
arrange for relevant inquiries, and assess whether the
test participants should cease taking the test drug.
Data that is to be collected from participants who have
discontinued the study as a result of an SAE: An object-
ive clinical evaluation of the skin will be undertaken; if
hypercalcaemia or hypercalciuria has arisen, this must
be confirmed by a blood test and an objective neuro-
logical investigation undertaken at the neurological de-
partment, University Hospital, Odense.
If an adrenal suppression or weakening of glycemic
control of diabetes mellitus has arisen, this must be con-
firmed by a blood test and an objective investigation
undertaken by the endocrinology department, University
Hospital, Odense. If a cataract or increased intraocular
pressure arises, this must be confirmed by an objective
ophthalmological investigation by the ophthalmology de-
partment, University Hospital, Odense.
An attempt will be made to replace discontinued par-
ticipants with new participants, so the desired total
number of participants can be reached. Participants who
are discontinued from the study due to the occurrence of
an SAE will be followed in the relevant medical depart-
ment with respect to what is estimated to be clinically
relevant by the departments to which the participants are
referred. Participants will be un-blinded at the time of
exclusion.
Randomization and blinding
Parallel-assigned block randomization (1:1) will be done
in eight blocks stratified by age and gender.
The randomization code will be stored with the data
manger and the randomization list will be made with a
computer-generated sequence in the randomization tool
REDCap Randomize.
While participants fill out the informed consent form,
the investigator will enter participants data into the
randomization tool REDCap randomize, which is set up
by Odense Patient data Explorative Network (OPEN),
and participants will be randomized with the help of the
data program in REDCap to participate in one of the
two arms of the trial.
The randomization code will be stored with the data
manager, who will assist with setting up the randomization
in REDCap in the OPEN system.
The trial master file (TMF) will contain information
on each test participant’s EM and study drug, stating the
batch numbers of the Cal/BD cutaneous foam canisters
supplied.
The randomization code will be stored in the randomization
tool REDCap Randomize. The trial investigator has no access
to the code.
Study drug
All study participants will be provided the study
medication Cal/BD cutaneous foam (Enstilar®), regis-
tered for topical treatment of psoriasis [29]. Cal/BD
cutaneous foam was chosen because the EM was de-
sign for the canister containing the Cal/BD cutaneous
foam. This, in turn, could help participants focus on
the testing of a new drug instead of focusing on the
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behavioral intervention. In the trial, both the inter-
vention and the non-intervention groups are treated
with the Cal/BD cutaneous foam, which is supplied
free of charge for 28 treatment sessions (1 x daily for
4 weeks), and thereafter for 1 prn hs. Treatment will
include a maximum of 15 g/day and will be supplied in an
aluminum canister with an EM attached. Total consump-
tion will be calculated at baseline: 0.5 g Cal/BD cutaneous
foam per body surface area (BSA), 1× daily for 4 weeks.
An agreement on the labelling of the test drug has been
made with the hospital pharmacy where the study labels
have been purchased and are produced in accordance with
GMP (good manufacturing practice) and Annex 13 [36] in
which information is provided that the trial involves a test
drug. Each canister of Cal/BD cutaneous foam will be
given sequentially numbered labels (starting from nos. 1,
2, 3, etc.). The study medication is listed in the TMF using
this identification number.
No placebo or reference compounds will be used in
the trial.
The effect on mild-to-moderate psoriasis treated daily
with Cal/BD cutaneous foam for 4 weeks has been in-
vestigated in three recently published trials [37–39]. By
using surrogate effect parametres for itching, life quality,
and reduction in the spread of psoriasis, it was found in
these studies that Cal/BD cutaneous foam was signifi-
cantly more effective than treatment with either Cal/BD
ointment (Daivobet®), vehicle alone, betamethasone in
foam, or calcipotriol in foam. However, Cal/BD cutane-
ous foam was not superior to comparable products for
the treatment of psoriasis of the scalp.
Description and justification of dose level, dose regimen
and frequency, and treatment period
The trial follows recommendations from the product re-
sume for Cal/BD cutaneous foam [29]. Patients with
mild-to-moderate psoriasis will be prescribed a treat-
ment of 1 x daily for 4 weeks, thereafter according to
need. Maximum consumption will be 15 g/day.
It is assessed that there are no risks connected with
the use of the EM and app.
Procedures for keeping tally of the study drug
Data entered into the TMF include a reference to
the batch numbers for the medicine supplied and
returned with one number for each canister of Cal/
BD cutaneous foam provided, subjects identified by
participant number and in the CRF, the EM-measured ad-
herence rate (number of days with applications in the
treatment period/number of days in the treatment period),
and a quantity of test drug used with reference to each
label number.
No placebos will be used in the study.
Screening for side-effects
The investigator will screen for known side-effects listed
in the product summary for Cal/BD cutaneous foam [29]
(Additional file 2) and adhere to instructions for reporting
of AEs, SAEs, serious adverse reactions (SARs), and sus-
pected unexpected serious adverse reactions (SUSAR)s.
Power of the study
In order for the app to increase adherence, we expect
that, over the 4 weeks of the intervention period, there
will be an 8% increased usage of Cal/BD cutaneous foam
in the intervention group compared with the non-
intervention group. Mean number of applications in the
intervention group will be 90% of the recommended
number of applications / 4 weeks, SD in the intervention
and non-intervention groups set at 15%, power (1 – β)
80%, C.I. (two-sided) 95%, ratio sample size 1, drop-outs
approx. 12.5%, total estimated test population of 134
participants.
The calculation of the required size of the test population
has been assessed by the principal investigator using Stata
Corp. 14.1.
Criteria for the conclusion of the study
The study will be concluded when 120 participants have
carried out the study, independent of the number of en-
rolled study participants with the latest inclusion of
study participants to be on 28 February 2018.
Procedures for reporting deviation from the original
statistical plan
If the desired number of study participants cannot be
achieved, it will be necessary to deviate from the ori-
ginal calculation of strength, and the level of signifi-
cance (p <0.05) will be lowered.
Statistical analysis
Data will be used from all the included participants who
sign informed consent forms at baseline. With respect to
isolated missing measurements, multiple imputations
will be used. If several treatment sessions are observed
on 1 day, an analysis for a maximum of 1 daily treatment
session will be conducted.
When data is collected, a test of significance will be
carried out using ITT analysis in regression models be-
tween means for the intervention and non-intervention
groups for the outcome measures: The LS-PGA and
DLQI endpoints and the difference in the overall usage
of Cal/BD cutaneous foam. If individual measurements
of endpoints are missing, multiple imputations will be
used to compensate for the missing data.
The analyses will be conducted by a statistician at
OPEN, who uses Stata Corp. 14.1 and is hired due to his
experience in analyzing data from RCTs.
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An interim analysis will not be conducted, since Cal/
BD cutaneous foam is used in relation to recorded, ap-
proved use, and it is not assessed that there is an in-
creased risk to the participants.
Study plan and design
At an ordinary consultation with patients referred to
the dermatology department, the investigator will
screen for suitable participants according to the in-
clusion criteria mentioned above. Before patients are
included in the study, informed consent will be ob-
tained at the baseline visit.
Informed consent
The investigator’s first contact with potential partici-
pants, who are legally competent and of sound mind,
will take place face-to-face at an individual consultation
prior to or at the baseline visit. The consultation will
take place in calm surroundings at an outpatient clinic,
where the investigator has no other duties at the depart-
ment. Prior to presenting the information, participants
will be informed of their right to make another appoint-
ment at which a companion (lay representative) is
present.
The investigator is responsible for ensuring that the
patient gets sufficient information about the study. This
information includes oral and written information.
Oral information: this information includes the
purpose, the risks and benefits of the study, possible
side-effects, plan for treatment, precautions, the re-
cording of information and duty of confidentiality,
compensation and grievance options, finances, volun-
tariness, and informed consent and the withdrawal
thereof. In addition, the patient will be informed of
the possibilities for treatment if the patient does not
wish to participate in the study.
Written information: Written information is provided
in forms entitled “Written participant information on
the study: An intervention study with the purpose of im-
proving the use of locally-applied steroid compounds by
psoriasis patients, Project ID S-20160068, Vs. 1.3” and
“Rights of participants in a health-related research pro-
ject,” published by the National Committee on Health
Research Ethics [40].
Patients shall be made aware of their right to deliber-
ate for 14 days and the opportunity to have any points
of doubt resolved.
When the patient has decided to become a participant
in the study, the patient in question must date and sign
the informed consent and deliver it personally to the in-
vestigator. The informed consent form is to be dated
and signed by the attesting doctor on the day the patient
is informed. When the patient and investigator have
signed the informed consent form, the patient must be
offered a photocopy of the consent form. The original
signed consent form must thereafter be stored along
with the participant’s CRF.
The investigator must write in the journal that the pa-
tient has signed an informed consent and authorization
form for participation in the project and the date thereof.
Information obtained and provided throughout the study
visits
At the baseline visit at the Dermatology Department
in Odense, the investigator MTS will collect informa-
tion from the patient journal on 1) the patient’s
current and previous use of medicine, 2) length of ill-
ness, 3) socio-economic condition (marital status and
educational level), 4) severity of disease, and 5) gen-
der and age. This information alone will form the
basis for a randomization control in order to ensure
that the non-intervention and intervention groups are
comparable.
Upon inclusion, all participants will be supplied free
of charge: 1) Cal/BD cutaneous foam for 4 weeks of
treatment and 2) an EM that is equipped with a can-
ister of Cal/BD cutaneous foam from the start of the
study.
No remuneration will be provided to the participants
beyond the free supply of Cal/BD cutaneous foam. The
Cal/BD cutaneous foam will be supplied by LEO® and
delivered to the trial site.
After the consultation, participants will be shown
into an adjacent room, where the laboratory assistant
face-to-face will explain the treatment plan and help
the participants who are randomized into the inter-
vention group to download the app. The laboratory
assistant will hand a diary for the intervention and
non-intervention groups, in which the participants
can write down any additional observations observed
during the first 4 weeks of treatment. The participant
in the intervention group will also be informed here
that the app is a proposed method to help them stick
to their treatment plan.
The following source data will be stored directly in
the CRF:
During consultation in week 4, participants will bring
the canisters containing the study drug Cal/BD cutane-
ous foam and the EM. The study drug will thereafter be
given to the laboratory technician associated with the
trial. The laboratory technician will ensure that the EM,
which contains information about the number of treat-
ment sessions in the first 4 weeks of the trial, is deliv-
ered to BridgeIT. BridgeIT will read the data and
provide it to the investigator and laboratory technicians,
who will transfer the data to the data storage tool
REDCap (Additional file 3).
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Other data from the EM on the usage pattern will
be stored by the EM and the app on a data key in a
locked filing cabinet with the investigator for later
data processing.
LEO® will ensure that the EM will be discarded after use
and will preserve no person-identifiable data from the EM.
For the individual participant, the trial will last
26 weeks. All study events are listed in Table 1 and out-
comes obtained at these events are listed in Fig. 1.
Study schedule
The study included its first participant on January 9,
2017, and the last participant visit is planned for
September 2017. Totally 134 participants have been in-
cluded, and a total of approximately 120 participants are
expected to complete the entire study period.
Discussion
To the best of our knowledge, this is the first trial of
whether an app can improve rates of adherence to a top-
ical antipsoriatic drug. If the app improves rates of ad-
herence and reduces the burden of psoriasis in a
clinically significant way, the app could easily be imple-
mented as a standard routine of care in the clinic.
For studies in adherence-increasing interventions, the
purpose of the trial should be blinded to the participant
from start of the study and during the study. Informing
the participants that they are being monitored should be
withheld until end of the study. This is necessary since
any knowledge that the participant is being monitored
may influence adherence [41]. In American studies of
medical adherence, previous committees on health
research ethics have approved studies in which partic-
ipants were never informed that they were being
monitored, and their informed consent was never
given [42]; while, in another study [43], information
was provided that monitoring was taking place and
informed consent was given only at the final study
visit. In a Danish study [16], the participatns were
not informed that they were in a study that measured
their medical adherence.
Specific ethical considerations in the study
Potential beneficial effects of the use of the app: If the
study can show that an app can improve adherence with
Patients recruited by direct Patients recruited by direct advertisement (N=144)
Not eligible for randomization (N=?)
Did not meet inclusion criteria (N=?)
Declined to participate (N=?)
Lost to follow-up (N=?)    
Randomized (N=?)
Returned for week 8 appointment (N=?)
Returned for week 4 appointment (N=?)
Assigned to Cal/BD foam + app (N=?) Assigned to Cal/BD foam (N=?)
Returned for week 4 appointment (N=?)
Lost to follow-up (N=?) Lost to follow-up (N=?)
Returned for week 8 appointment (N=?)
Returned for week 26 appointment (N=?) Returned for week 26 appointment (N=?) 
Lost to follow-up (N=?)  
Lost to follow-up (N=?)              Lost to follow-up (N=?)                                     
Missing data: adherence rate chip (n=?), weight (n=?), and 
patient-reported (n=?); LS-PGA (n=?); DLQI (n=?)
Missing data: adherence rate chip (n=?), weight (n=?), and 
patient-reported (n=?); LS-PGA (n=?); DLQI (n=?)
Missing data: LS-PGA (n=?); DLQI (n=?) Missing data: LS-PGA (n=?); DLQI (n=?)
Missing data: LS-PGA (n=?); DLQI (n=?)                               Missing data: LS-PGA (n=?); DLQI (n=?)                              
Fig. 1 Flow of participants during the trial period
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respect to locally-treated psoriasis, the study will show if
this is followed by a diminished extent of disease and
improved quality of life.
The app developed by a commercial firm: The app de-
veloped by the pharmaceutical industry can be imple-
mented in the clinic without cost for the public health
system.
It can be seen as a disadvantage that the app was de-
veloped and is owned by the pharmaceutical industry.
The public health authorities, however, will be able to
draw experience from the test app and be inspired to de-
velop similar patient-supporting apps.
Disadvantages about use of the app are that data re-
specting the patient’s use of the app are stored by the
owner, the pharmaceutical industry. However, informa-
tion about use is only connected to gender, age, and the
spread of the disease without additional personally iden-
tifiable data.
It is estimated that potential advantages to the use of
the app (improved medical adherence) outweigh any dis-
advantages about using the app.
Scientific insight achieved by the study - from an ethical
perspective: Topical corticosteroids are safe and effective
when they are used as prescribed. However, if the patient
has a lack of efficacy from the prescribed treatment with a
topical corticosteroid, it may be due to non-adherence. If
the clinician is not attentive to this, the next step will be to
subject the patient to treatments that have a risk of skin
cancer or burns (for example, Ultaviolet B (UVB) photo-
therapy treatment), potentially dangerous treatments that
have a risk of immunosuppression, pancytopenia and liver
damage (for example, methotrexate), a high risk of exten-
sive fetal damage, dry skin and hair loss (for example, aci-
tretin), and financially cost-intensive treatments without
knowledge of long-term side-effects (for example, biological
treatments or apremilast).
Additional files
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Data Set. (PDF 384 kb)
Additional file 2: Screening and reporting of adverse events (AEs).
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business partners, and public authorities providing assistance for the
study. (PDF 247 kb)
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